These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 6757081)
1. Improvement of artificial endocrine pancreas (Biostator; GCIIS) performance combining feedback controlled insulin administration with a pre-programmed insulin infusion. Calabrese G; Bueti A; Zega G; Giombolini A; Bellomo G; Antonella MA; Massi-Benedetti M; Brunetti P Horm Metab Res; 1982 Oct; 14(10):505-7. PubMed ID: 6757081 [TBL] [Abstract][Full Text] [Related]
2. [Use of the endocrine artificial pancreas (GCIIS; Biostator) in heart surgery]. Calabrese G; Bueti A; Zega G; Bellomo G; Antonella MA; Giombolini A; Tardioli F; Massi-Benedetti M; Palminiello A Minerva Med; 1982 Dec; 73(49-50):3509-14. PubMed ID: 7155400 [TBL] [Abstract][Full Text] [Related]
3. Long-term improvement in metabolic control of unstable type I diabetes by s.c. insulin injection patterns based on the dose profiles required by bed-side artificial beta-cell. Bombor H; Bruns W; Ratzmann KP; Jutzi E; Albrecht G; Michaelis D; Fischer U Exp Clin Endocrinol; 1984 Apr; 83(2):143-51. PubMed ID: 6373316 [TBL] [Abstract][Full Text] [Related]
4. [Insulin needs of insulin-dependent diabetics during biostator control and subcutaneous use of insulin]. Petkova M; Khristov V; Tsanev A Vutr Boles; 1990; 29(1):74-7. PubMed ID: 2204207 [TBL] [Abstract][Full Text] [Related]
5. [Blood-sugar-controlled insulin infusion systems for rapid adjustment of insulin-dependent diabetics (author's transl)]. Beyer J; Becker G; Schulz G; Gaberle E; Wolf E; Hassinger W; Cordes U Dtsch Med Wochenschr; 1981 Dec; 106(49):1644-9. PubMed ID: 7030687 [TBL] [Abstract][Full Text] [Related]
6. [Analysis of the daily insulin requirements as determined by a biostator (artificial pancreas) in patients with insulin-dependent diabetes mellitus]. Djurić DS; Mićić JV; Micić D; Brkić V; Nesović M; Djordjević P; Dragasević M Srp Arh Celok Lek; 1983; 111(9-10):1351-60. PubMed ID: 6399414 [No Abstract] [Full Text] [Related]
7. Comparison of 24-hour insulin requirements in IDDM patients during control by an artificial betacell and during conventional therapy. Christiansen JS; Svendsen PA; Mathiesen E; Rubin P; Deckert T Horm Metab Res; 1981 Oct; 13(10):537-41. PubMed ID: 7028586 [TBL] [Abstract][Full Text] [Related]
8. [Use of the artificial endocrine pancreas in the clinic]. Tsanev A; Zlateva S; Khristov V; Petkova M Vutr Boles; 1985; 24(6):107-11. PubMed ID: 4095982 [TBL] [Abstract][Full Text] [Related]
9. [Various biohumoral parameters (blood triglycerides, blood cholesterol, blood uric acid, blood electrolytes) after automatic control by an artificial pancreas in subjects with type I diabetes mellitus]. Sinagra D; Amato MP; Cangemi C; La Sala MS Boll Soc Ital Biol Sper; 1984 Sep; 60(9):1691-5. PubMed ID: 6525287 [TBL] [Abstract][Full Text] [Related]
10. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues. Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931 [TBL] [Abstract][Full Text] [Related]
11. Determination of 24-hour insulin infusion pattern by an artificial endocrine pancreas for intravenous insulin infusion with a miniature pump. Kølendorf K; Christiansen JS; Bojsen J; Svendsen PA; Teglbjaerg LL Horm Metab Res; 1981 May; 13(5):245-9. PubMed ID: 7021384 [TBL] [Abstract][Full Text] [Related]
12. [Guidelines concerning insulin dosage in children and adolescents with type 1 diabetes on continuous subcutaneous insulin infusion]. Szypowska A; Pańkowska E; Lipka M Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(1):45-50. PubMed ID: 16704861 [TBL] [Abstract][Full Text] [Related]
13. The effect of three days of blood glucose normalization by means of an "artificial endocrine pancreas" on the concentrations of growth hormone, glucagon, and cortisol in juvenile diabetics. Schock A; Schultz M; Kerner W; Maier V; Pfeiffer EF Horm Metab Res Suppl; 1979; (8):93-6. PubMed ID: 395097 [TBL] [Abstract][Full Text] [Related]
14. [Evaluation of the insulin requirements with an artificial pancreas in the pregnant woman with gestational insulin-dependent diabetes (type I)]. Fernández I; Gutiérrez A; Rodríguez MA; Costa CJ; Sánchez Ramos J; Durán García S Med Clin (Barc); 1989 Jun; 93(3):88-92. PubMed ID: 2677543 [TBL] [Abstract][Full Text] [Related]
15. Continuous intravenous insulin therapy with a miniaturized open-loop system. Renner R; Hepp KD; Mehnert H; Franetzki M Horm Metab Res Suppl; 1979; (8):186-90. PubMed ID: 395077 [TBL] [Abstract][Full Text] [Related]
16. [Early post-prandial hyperglycemic response: from case reports of insulin-dependent diabetics evaluated with an artificial pancreas]. Sinagra D; La Sala MS; Cangemi C; Amato MP Boll Soc Ital Biol Sper; 1984 May; 60(5):913-8. PubMed ID: 6466472 [TBL] [Abstract][Full Text] [Related]
17. Long-term application of wearable artificial endocrine pancreas--closed-loop intravenous vs subcutaneous insulin infusion. Shichiri M; Kawamori R; Goriya Y; Yamasaki Y; Nomura M; Asakawa N; Kubota M; Kamada T Life Support Syst; 1985; 3 Suppl 1():583-7. PubMed ID: 3916624 [TBL] [Abstract][Full Text] [Related]
18. Substitution of basal delivery of insulin by proinsulin in type I diabetic patients under CSII. Kerner W; Wallmüller G; Beischer W; Pfeiffer EF Horm Metab Res Suppl; 1988; 18():74-7. PubMed ID: 3056816 [TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the insulin requirements with an artificial pancreas in gestational diabetes]. Fernández I; Rodríguez MA; Gutiérrez A; Costa CJ; Sánchez Ramos J; Durán García S Med Clin (Barc); 1989 Jun; 93(4):129-33. PubMed ID: 2677545 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]